Mytrus, Inc. is a clinical innovations technology and services company. The company offers Mytrus Enroll, an electronic informed consent and patient enrollment system for clinical trials that enables patients to learn the details of informed consent, as well as creates an environment for a focused and productive conversation with study staff. It provides solutions for pharmaceutical, biotech, and device makers. The company was founded in 2009 and is based in Davis, California.
105 East Street
Davis, CA 95616
Founded in 2009
Britain's National Health Service Approves the Use of Mytrus Technology for Electronic Informed Consent in Clinical Trials
Aug 27 15
Mytrus announced that its software platform for electronic informed consent has received approval for use by Britain's National Health Service (NHS). It is the first time e-Consent technology will be used in a trial in England. Mytrus was also the first electronic informed consent technology approved for use in a clinical trial by the U.S. Food and Drug Administration in 2011. It has since been used by some of the world's largest pharmaceutical companies in about 30 studies and received approvals from other national health authorities, as well as 50 institutional review boards and ethics committees. inVentiv Health is an investor in Mytrus and integrates its pioneering technology to help clients improve clinical trial execution, speed time to market and reduce product development costs. Approval for the use of Mytrus' electronic informed consent in the trial in England was granted by the Health Research Authority (HRA), a division of Britain's NHS. Mytrus' Enroll® 2.0 iOS software platform uses a tablet device to give potential participants a trial overview that includes simple, entertaining videos to reinforce key information. People read the informed consent document, answer questions to assess understanding and are prompted to review information they don't understand as well. Research site staff can track patient metrics to better understand where patients need counseling and dedicate time for each potential study participant to discuss the study with site staff before agreeing to sign consent. The study using Mytrus' Enroll® 2.0 iOS software platform and web portal began enrolling patients in July. It is being conducted by a top-ten, global pharmaceutical company to determine the safety of a new investigational drug. The e-Consent pilot is being run in tandem with traditional paper consent so that results can be compared. An independent study conducted by the California Pacific Medical Center Research Institute using Enroll® found that patients provided with paper-only consent were able to correctly answer 58% of the questions asked on a follow up questionnaire, versus those who used an electronic consent application could correctly answer 75% of the questions. Drug companies seeking ways to manage soaring development costs can look to Mytrus technology to increase efficiency and improve the patient enrollment experience. In addition, Mytrus' Enroll® provides a variety of significant benefits in improving site performance, with the ability to expedite study start times and enhance regulatory compliance. The technology provides insights to improve relationship management with trial sites and allow sponsors to offer richer, deeper information to regulatory authorities at every step on the path from trial to commercialization. Mytrus technology has been used by 8 out of the world's 10 large pharmaceutical companies to improve patient enrollment in clinical trials. Most recently, Mytrus was selected for a pilot project by the oncology clinics at New York-Presbyterian/Weill Cornell Medical Center's Joint Clinical Trials Office. They will use Mytrus' Enroll® to streamline the enrollment process for doctors and researchers and enable them to track consent status for future research.
Mytrus, Inc. Creates New Innovation Advisory Board
Mar 18 14
Mytrus, Inc. announced the creation of a new Innovation Advisory Board comprised of industry experts who will help shape the future of clinical products and services offered by the company. The six Innovation Advisory Board members include: Steven Cummings, MD is co-founder of Mytrus and an expert in the design and implementation of clinical research studies. Dr. Cummings, the Chief Scientific Officer at Mytrus, also serves as Director of the San Francisco Coordinating Center, Emeritus Professor of Medicine, Epidemiology and Biostatistics at UCSF and Senior Scientist at CPMC Research Institute and Innovator-in-Residence at Roche-Genentech. David G. Forster, JD, MA, CIP, Chief Compliance Officer, WIRB-Copernicus Group joined the Western Institutional Review Board in 1996 and currently serves as Chief Compliance Officer as well as a co-chair on a subcommittee of the Health and Human Services Secretary's Advisory Committee on Human Research Protections. Clay Johnston, MD, PhD is Dean of Medicine at the new University of Texas Dell Medical School in Austin. Dr. Johnston recently served as Director of the Clinical Translational Sciences Institute at the University of California, San Francisco, and an expert in clinical trial methods. Garry Neil, MD is Global Head of Research and Development at Medgenics and a leader in clinical trials innovation. At Johnson & Johnson, he served as Corporate Vice President of Science & Technology and Group President of Pharmaceutical Research and Development. Dr. Neil also is a Founder/Director and served as CEO of TransCelerate Biopharma Inc. Dr. John Orloff, MD is Global Head of Clinical Development at Merck Serono. Dr. Orloff recently served as Chief Medical Officer and Senior Vice President, Global Development for Novartis Pharma AG where he led the 'Trials of the Future' initiative to bring innovation to the drug development process. He also served as Head of U.S. Medical and Drug Regulatory Affairs for North America. Jane Perlmutter, PhD, MBA is a psychologist and leading patient advocate for clinical trial participants. Dr. Perlumutter also serves on the Clinical Trials Transformation Initiative on Informed Consent.